Sanjay Nayak - 12 Feb 2026 Form 4 Insider Report for OCULAR THERAPEUTIX, INC (OCUL)

Role
Chief Strategy Officer
Signature
/s/ Todd Anderman, Attorney-in-Fact for Sanjay Nayak
Issuer symbol
OCUL
Transactions as of
12 Feb 2026
Net transactions value
-$93,546
Form type
4
Filing time
17 Feb 2026, 20:30:26 UTC
Previous filing
06 Jan 2026
Next filing
25 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Nayak Sanjay Chief Strategy Officer C/O OCULAR THERAPEUTIX, INC., 15 CROSBY DRIVE, BEDFORD /s/ Todd Anderman, Attorney-in-Fact for Sanjay Nayak 17 Feb 2026 0002012715

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction OCUL Common Stock Sale $93,546 -10,348 -3% $9.04 332,412 12 Feb 2026 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Represents shares of common stock of Ocular Therapeutix, Inc. (the "Corporation") sold, pursuant to a durable automatic sale instruction adopted by the reporting person on February 21, 2024, effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations in connection with the vesting of restricted stock units on February 11, 2026. The sales do not represent a discretionary trade by the reporting person.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.9950 to $9.0873, inclusive. The reporting person undertakes to provide to the Corporation, any security holder of the Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.